STERIS plc $STE Shares Bought by NEOS Investment Management LLC

NEOS Investment Management LLC raised its stake in shares of STERIS plc (NYSE:STE) by 42.6% in the third quarter, Holdings Channel.com reports. The fund owned 11,997 shares of the medical equipment provider’s stock after purchasing an additional 3,586 shares during the period. NEOS Investment Management LLC’s holdings in STERIS were worth $2,969,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in shares of STERIS during the 2nd quarter worth approximately $289,132,000. Orbis Allan Gray Ltd lifted its stake in STERIS by 36.0% during the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after purchasing an additional 556,088 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of STERIS by 246.4% during the third quarter. Thrivent Financial for Lutherans now owns 553,834 shares of the medical equipment provider’s stock worth $137,041,000 after buying an additional 393,970 shares during the period. Invesco Ltd. grew its stake in shares of STERIS by 32.2% in the second quarter. Invesco Ltd. now owns 1,220,699 shares of the medical equipment provider’s stock valued at $293,236,000 after buying an additional 297,076 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of STERIS by 305.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 330,907 shares of the medical equipment provider’s stock valued at $81,880,000 after buying an additional 249,386 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Price Performance

Shares of NYSE STE opened at $250.99 on Friday. STERIS plc has a 52 week low of $204.90 and a 52 week high of $269.44. The stock has a market cap of $24.61 billion, a price-to-earnings ratio of 35.01 and a beta of 1.03. The company’s 50-day moving average price is $256.13 and its 200 day moving average price is $250.93. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The company’s revenue for the quarter was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, research analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, February 17th. STERIS’s payout ratio is presently 35.15%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and an average price target of $275.20.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.